Drug Combination Details
| General Information of the Combination (ID: C84861) | |||||
|---|---|---|---|---|---|
| Name | Ursolic acid NP Info | + | Temozolomide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MGMT | Molecule Info | ||
| In-vitro Model | LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | ||
| LN-18 | CVCL_0392 | Glioblastoma | Homo sapiens | |||
| T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
| In-vivo Model | LN18 cells (5*106/mouse) were subcutaneously injected into the left hind flank of each female BALB/c mouse. | |||||
| Experimental
Result(s) |
Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression. | |||||
